Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report

Atezolizumab is a monoclonal antibody immune checkpoint inhibitor that binds to programmed death ligand 1 to selectively prevent its interaction with programmed cell death-1 (PD-1) and B7.1 (CD80) receptors. We present a case of a 61-year-old man with metastatic urothelial carcinoma of the right ure...

Descripción completa

Detalles Bibliográficos
Autores principales: Rkman, Deni, Likić, Robert, Bebek, Marko, Gnjidić, Milena, Gamulin, Marija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952903/
https://www.ncbi.nlm.nih.gov/pubmed/31894921
http://dx.doi.org/10.3325/cmj.2019.60.552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952903/
https://www.ncbi.nlm.nih.gov/pubmed/31894921
http://dx.doi.org/10.3325/cmj.2019.60.552

Ejemplares similares